StockNews.AI
BDMD
StockNews.AI
127 days

Baird Medical Presents Advanced MWA Technology to UCLA Expert in China

1. Baird Medical hosted Dr. Tse to discuss microwave ablation technology. 2. Dr. Tse observed thyroid procedures, gaining insights on clinical efficacy. 3. The visit underscores Baird Medical's commitment to global partnerships. 4. Baird Medical leads in thyroid ablation devices internationally. 5. The company aims to enhance minimally invasive treatments worldwide.

9m saved
Insight
Article

FAQ

Why Bullish?

The collaboration with Dr. Tse highlights Baird Medical's innovative technology and global credibility, potentially increasing investor interest in BDMD and driving its stock price upward. Similar positive impacts have been observed in companies like Intuitive Surgical after engaging respected medical figures.

How important is it?

The article emphasizes Baird's technological advancements and global positioning, crucial for stakeholder confidence and market traction. It reflects positively on management's strategic vision and execution, enhancing BDMD's attractiveness to investors.

Why Long Term?

The implications of global partnerships and technological advancements will likely unfold over several quarters, similar to historical trends where long-term innovations show gradual market acceptance and growth, as seen with many biotech firms.

Related Companies

ISRGABTMDT
, /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company") recently hosted Dr. Gary G. Tse, a distinguished interventional radiologist from UCLA Health, for an immersive clinical visit in Guangzhou, China. The visit highlighted Baird Medical's cutting-edge microwave ablation (MWA) technology and its growing role in minimally invasive thyroid treatments. Dr. Gary Tse with local experts Dr. Tse observed multiple thyroid nodule ablation procedures at Sun Yat-sen University Cancer Center, gaining valuable insights into the precision and clinical efficacy of Baird Medical's MWA system. In addition to the procedural observations, Dr. Tse participated in academic discussions with Dr. Michael Mingzhao Xing, Professor Emeritus at the Johns Hopkins University School of Medicine. Together, they explored the latest advancements and clinical outcomes in thyroid nodule management. Dr. Tse's visit reinforces Baird Medical's commitment to fostering partnerships with leading medical experts worldwide. As the Company continues its global expansion, it remains dedicated to enhancing the accessibility and effectiveness of minimally invasive treatments for thyroid conditions. About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:Eric Huang, PR LiaisonBaird Medical Investment Holdings Ltd.Phone: +1 (888) 508-6228Email: [email protected]SOURCE BDMD WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News